Chapter 27: Pharmacological Treatment of Respiratory Disorders

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Breathing.

It's the most fundamental thing we do, right?

You do it something like 20 ,000 times a day.

Inhale.

Exhale.

Just repeat.

And most of the time you don't even think about it.

It's just this background rhythm to your life.

It's totally automatic.

Invisible.

Exactly.

But for millions of people, that automatic process is a conscious struggle every single day.

And, you know, until you can't breathe, until that rhythm is broken, you just don't realize how fragile that whole system is.

That's absolutely right.

We take it for granted.

But the respiratory system is, I mean, it's basically a biological battleground.

When we talk about these disorders, asthma, COPD, cystic fibrosis, we're not just talking about being a little out of breath.

We are talking about, you know, serious obstruction, intense inflammation, and this physiological panic state where the body is literally fighting its own ability to get oxygen.

The stakes are incredibly high and the biology behind it is fascinatingly complex.

And that is exactly where pharmacology comes in.

Today, we're not just going to read a list of drug names off a page.

We are going on a mission, really, to understand how we can chemically, you know, manipulate the lungs to stay open, right?

We're taking a deep dive into Chapter 27 of Brenner and Stevens Pharmacology, the sixth edition.

So you should think of this as your last minute lecture.

Yeah, that's a good way to put it.

Whether you're a med student cramming for boards, a clinician who wants a refresher on the mechanisms, or you're just, you know, deeply curious about how an inhaler actually saves someone's life, we are going to break it down for you.

And it's a dense chapter, I won't lie.

It covers, I mean, everything from the cellular cascade of an allergic reaction all the way to genetic breakthroughs and cystic fibrosis.

But there is a real logic to it.

If you look closely, we're not just memorizing facts, we're understanding the why behind the treatment.

Okay, so help us navigate that logic.

What's our roadmap for this deep dive?

How are we going to tackle this, this beast of a chapter?

Okay, so to keep it organized, we'll break it down into, say, four main phases.

First, we have to understand the battlefield,

the pathophysiology.

What's actually going wrong in the lungs?

Exactly.

What is physically happening in an asthmatic lung versus a lung with COPD?

Because if you don't get the problem, the drugs are just names, they don't make any sense.

Right.

So once we get the problem, we can look at the solutions.

Phase two is what I call the anti -inflammatory squad.

This is your corticosteroids, your mast cell stabilizers, and the leukotrine inhibitors.

So the drugs that calm all the swelling down.

Precisely.

Then phase three, the bronchodilators.

These are the drugs that physically relax the muscle to pry the airways open.

That's your beta agonists, your muscarinics, and theophylline.

And then finally, phase four, we'll get to the heavy hitters, the monoclonal antibodies.

We'll touch on symptom management for things like coughs and colds, and we'll close out with a really fascinating look at cytistic fibrosis treatments, which is where pharmacology starts to feel a bit like science fiction.

I love it.

Okay, and just a quick disclaimer before we really jump in.

We are sticking strictly to the texts provided in chapter 27 of Brenner and Stevens.

We are not doctors giving medical advice for your specific cough.

No.

And we're not bringing in outside research or brand new drugs that haven't made it into this edition.

We're here to help you master this specific source material.

That's the goal.

Okay, let's get into the trenches.

Section one, the battlefield,

an overview of respiratory disorders.

Right.

So the chapter gives us a broad scope.

It's looking at asthma, chronic obstructive pulmonary disease, COPD,

rhinitis, which is, you know, your common runny nose, and cystic fibrosis.

But let's start with the big one, the one that really dominates the text, asthma.

I think most people have a general idea what asthma looks like, you know, the wheezing, the coughing, being short of breath.

But what's the textbook definition we really need to nail down?

What separates it from just having a really bad cold?

Okay, so the text defines it by three very specific characteristics.

You have airway obstruction, you have inflammation,

and you have increased responsiveness to stimulate.

Okay, responsiveness.

What does that mean exactly?

It's the key.

That responsiveness is what makes it asthma.

A person without asthma breathes in cold air,

and well, nothing happens.

An asthmatic breathes in that same cold air or, you know, encounters allergens or exercises or even just gets emotional stress, and their airways basically panic and slam shut.

They overreact.

Talk to me about the cellular cascade.

I love that term.

It sounds like a tiny biological war.

When that trigger hits, let's say it's a cloud of pollen,

what is happening at the microscopic level?

It is absolutely a war.

It's a domino effect.

In a person who's susceptible, that trigger causes the release of this massive cocktail of substances from their immune cell.

Which cells are we talking about?

We're talking specifically about mast cells, ecionophils, basophils, neutrophils, and You can think of them as the security guards of the lungs, but in asthma they are.

They're overly aggressive.

They're trigger -happy.

Okay, and what kind of ingredients are in this cocktail that they're releasing?

What's in the chemical weapons here?

It's a mix of things.

You have stored grenades, and you have newly manufactured weapons.

So first, you have substances that are already packed and stored in these little granules inside the cells.

Things like histamine, adenosine, Bridehackenin, and something called major basic protein.

The second that trigger hits, those are released immediately.

Boom.

Instant effect.

Instant.

But then, the body starts manufacturing brand new inflammatory agents.

These are derived from something called arachidonic acid, and specifically we're talking about leukotrienes and prostaglandins.

And what does this whole chemical soup actually do to the lungs?

Why can't I breathe when all of this is happening?

It causes three main physical changes.

One, you get inflammation of the airway tissue itself.

It gets red and swollen.

Two, you get edema and desquamation.

Desqua -what?

Desquamation.

It's a fancy way of saying the lining of the bronchial epithelium, the inner skin of your airways, starts to peel off or shed.

Yikes.

Yeah.

And three, you get hypertrophy of the smooth muscles.

Basically, the muscle walls of your airways get thick, they get swollen, and they get really twitchy.

Twitchy is a great word for it, and a terrifying one.

Now, the text brings up something called the biphasic reduction in pulmonary function.

This seems like a really important concept for understanding why asthma can be so dangerous.

Can you unpack that for us?

This is absolutely critical for anyone treating asthma to understand.

Biphasic just means two phases, so you have the early phase.

This happens fast within, say, 10 to 30 minutes of being exposed to the allergen.

It lasts for maybe two or three hours.

Yes, that's the immediate, I can't breathe reaction where the airways constrict.

But then, then there's a late phase, and this occurs two to eight hours after the initial exposure.

Sweet.

You could use your rescue inhaler, feel completely better, and then eight hours later, when you think you're in the clear, you're suddenly in trouble again.

Exactly.

And the text really emphasizes this point.

This late phase is believed to be responsible for inducing and maintaining that bronchial hyperreactivity we talked about.

So it's not just a second attack.

No, it's worse.

It sets the lung up to be even more sensitive the next time.

It's sort of reprogramming the lung to be more reactive in the future.

And here's a really sobering statistic from the chapter.

Nearly 70 % of asthma -related deaths happen at night.

70%.

That is a huge number.

Why at night?

Is it just because people are asleep and they don't notice the symptoms starting?

That's part of it, but it's actually more physiological than that.

It's due to circadian variations.

Our internal body clock.

Right.

Your bronchial responsiveness, how twitchy your airways are, it naturally changes throughout the day.

And for some patients, they can have an eight -fold increase in airway hyperresponsiveness at night.

It's a nocturnal danger zone.

Wow.

That really puts the importance of long -acting drugs into perspective, which I know we'll get to.

Okay.

Let's pivot from asthma to COPD.

How does the text differentiate the two?

Because on the surface, they both just seem like trouble breathing.

Yeah.

They can't look similar, but the underlying pathology is different.

So COPD is actually an umbrella term that covers two main conditions,

chronic bronchitis and emphysema.

Chronic bronchitis is defined by inflammation of the bronchioles and a productive cough.

Lots of mucus.

Emphysema is different.

It's the actual permanent destruction and enlargement of the air spaces, the alveoli themselves.

The tissue is destroyed.

And what's the key difference from asthma, then?

The big takeaway.

Reversibility.

In asthma, the obstruction is largely reversible.

You give a drug, the airway opens back up.

In COPD, that obstruction is largely irreversible.

Because you've actually destroyed lung tissue.

Exactly.

You've destroyed tissue or permanently altered it.

The text points out that smoking and advanced age are the primary risk factors.

However, and this is important, there is a small portion of obstruction in COPD that's caused by smooth muscle spasm and inflammation, and that part can be reversed.

And that's why we still use bronchodilators for these patients.

We're trying to maximize whatever function they have left.

Got it.

And just briefly, what about rhinitis?

It's just inflammation of the nasal mucous membranes.

You get sneezing, congestion, rhinorrhea, a runny nose.

It can be allergic, you know, reacting to pollen or dust mites, or it can be viral, like the common cold, which is usually caused by rhinoviruses.

Okay, before we jump into the drugs themselves, I want to visualize this.

The text gives us Box 27 .1, which is a case presentation of a 12 -year -old boy.

I feel like these case studies really help lock the information in.

What's the story with this kid?

So picture a 12 -year -old boy.

He's brought into his pediatrician because he's been having these recent episodes of coughing, wheezing, and shortness of breath.

It's happening maybe two or three times a week, and it's usually when he's outside playing.

He also has a family history of allergies to molds and pollens.

Physically, he looks fine.

He's alert, normal height and weight.

But when the doctor listens to his lungs with a stethoscope, she hears these fine wheezes during a forced expiration.

So they suspect asthma.

They'll run some numbers on him to confirm it, right?

Spirometry.

Right.

They do the spirometry tests.

His FEV1, that's the forced expiratory volume in one second, is at 85 % of what it should be for a boy his age and size.

That's the predicted value.

And his peak expiratory flow, or PEF, shows a variability of 20%.

What does that 20 % variability tell the doctor?

What's the significance?

Well, normal variability is less than 20%.

So the fact that his is right at 20 % confirms the diagnosis of mild asthma.

And it's most likely being precipitated by his allergies and by exercise.

Makes sense, since it happens when he's playing outside.

So what's the treatment plan they come up with for him?

They decide on Montelucast for daily maintenance therapy and an albuterol inhaler for rescue during any acute episodes.

OK, why Montelucast?

I feel like most people think of a steroid inhaler first.

Why go this route?

The text specifically notes they chose a leukotrine receptor antagonist.

That's the class Montelucast is in because of convenience.

Could be.

Yeah.

It's an oral pill you take once a day.

It's not an inhaler.

For a 12 -year -old kid, that can be a lot easier to manage.

It has a good safety profile and it's been shown to be effective in children.

It's a really great example of tailoring the drug choice to the patient's lifestyle.

I mean, if the kid won't use the inhaler correctly, it's not going to work no matter how good the drug is.

A pill is much easier to track.

That makes a lot of sense.

OK, let's move into section two, then.

The anti -inflammatory drugs.

And we're starting with the heavyweights.

The corticosteroids.

For moderate to severe asthma, these are absolutely the cornerstone of therapy.

They are the most efficacious anti -inflammatory drugs available.

Full stop.

We have a visual in the text for this, figure 27 .1, that shows the mechanism of action.

And it looks like corticosteroids are doing, well, basically everything.

It's not a simple lock and key mechanism, is it?

No, not at all.

It acts deep inside the cell.

Corticosteroids don't just work on one receptor on the cell membrane.

They work at a genetic and cellular level.

The diagram shows them inhibiting T -cell activation,

inhibiting cytokine production,

stopping eosinophil recruitment, preventing mast cell migration.

It's a very broad effect.

So they aren't just telling the muscle to relax.

They're going back to the source and turning off the entire alarm system.

That's a perfect analogy.

They work to reduce the number and the severity of symptoms, and they decrease the need for those rescue inhalers.

But, and this is a really big but, they have the potential for significant adverse effects if they're given systemically.

Systemically meaning like a pill or an injection.

Exactly.

Orally or by IV.

Which is why we inhale them for asthma.

Exactly.

Inhalation delivers the drug directly to the lungs, right, where the problem is.

And it minimizes the amount that gets absorbed into the general circulation.

The common inhaled drugs listed here are fluticasone, bucinide, and beclomethazone.

Now, the text makes a really big deal about using a spacer device.

It sounds like a simple piece of plastic tube.

But why is it emphasized so much?

It is absolutely crucial, both for efficacy and for safety.

When you press down on an inhaler, the propellant shoots the drug out at a very high velocity.

Right.

Without a spacer, a lot of that drug can just smack into the back of your throat and stay there.

A spacer is a holding chamber that goes between your mouth and the inhaler.

It slows those drug particles down, which does two things.

It decreases the amount deposited in your mouth, and it increases the amount that actually gets down into the bronchioles where it's needed.

And what happens if all that steroid gets deposited in your mouth?

You risk getting oral candidiasis, which is more commonly known as thrush.

A fungal infection.

Yes, a fungal infection caused by the local immunosuppression from the steroids sitting there.

Using a spacer and also rinsing your mouth out with water after you use the inhaler helps prevent that.

What about safety in kids?

I feel like every parent worries that putting their child on a steroid will stunt their growth.

What does the text actually say about that data?

The text addresses this head on because it is a valid concern and it comes up all the time.

There has been worry about potential growth suppression.

However, they cite a meta -analysis that looked at 21 different studies.

What did it find?

It concluded that inhaled Biclomethazone did not cause growth impairment.

There was another study they mentioned that showed 95 % of children who received inhaled Budsenide for an average of nine years.

They still reached their target adult height, even if there was some initial minor growth retardation early on.

So there might be a little bit of a delay at the beginning, but they ultimately catch up.

That seems to be the consensus presented in the text, yeah.

The risk of untreated asthma,

hypoxia, hospitalizations, missing school, is generally considered to be much, much higher than the risk from the drug itself.

That's a good perspective.

Before we leave the steroids, can you mention the combination products?

Right.

This is a very common strategy now for chronic therapy.

You combine a corticosteroid with a long -acting beta agonist, or LB, all in one single inhaler.

So one puff, two drugs.

Exactly.

The text lists fluticasone with salmetarol.

You might know that as adver or Budsenide with formotarol.

It just simplifies the whole regimen.

One puff does both the anti -inflammatory work and the bronchodilation work.

Very efficient.

Okay, section three.

Let's talk about mast cell stabilizers.

These drugs sound like they're, I don't know, reinforcing the walls of a fortress or something.

That is a really good analogy.

The drugs here are cromolin sodium, lidoxamide, and netocromyl.

Their mechanism is fascinating.

They literally stabilize the plasma membrane of the mast cell.

Specifically, they work by blocking calcium influx.

And why is blocking calcium so important here?

Calcium is the trigger for degranulation.

You can think of it as the signal for the mast cell to explode and release its payload of histamine and leukotrenes.

So if you block calcium from getting into the cell, the cell can't get the signal to dump its contents.

Ah, okay.

But the text makes a very, very specific point about when you have to take these drugs for them to work.

Yes, this is key.

They are prophylactic only.

They do not relax muscles that are already constricted.

They do not block histamine once it's already been released.

You have to take them before you're exposed to the trigger.

So if you're already in the middle of an asthma attack.

Cromolin is completely useless.

So if I have exercise -induced asthma, I would need to take it when?

You'd inhale it one hour or less before you go for a run.

Not after.

And are they safe?

Remarkably safe, actually.

Cromolin is very insoluble.

Even if you swallow some of it, only about 1 % is actually absorbed into the body.

So it's very non -toxic.

It's mostly used for mild to moderate asthma or allergic rhinitis.

You'll also see it formulated as eye drops for things like seasonal conjunctivitis.

Okay, moving on.

Section four, the leukotrine inhibitors.

We already met Montelukas with our 12 -year -old patient.

Let's get into the weeds of this arachidonic acid connection.

Right.

So to really understand these drugs, you have to look at figure 27 .2 in the chapter.

When a trigger hits a cell, phospholipids in the cell membrane get converted by an enzyme called phospholipase A2 into something called arachidonic acid.

Then another enzyme, this one is called 5 -lipoxygenase, takes that arachidonic acid and turns it into leukotrienes.

And what do these leukotrienes do that's so bad?

They are bad news for an asthmatic.

They recruit white blood cells to the area, which causes more inflammation.

They increase mucus secretion, making everything sticky.

They increase vascular permeability, causing swelling.

And they cause sustained bronchoconstriction.

They are incredibly potent inflammatory mediators.

So the chapter lays out two different ways we can stop them, right?

Two different strategies.

Correct.

Method one is to block the receptor.

That's what Montelukas and Xaprolukas do.

They physically sit on the Cysosal T1 receptor so that the leukotrienes, specifically C4, D4, and E4, can't bind to it and do their damage.

And what's method two?

Stop them from being made in the first place.

That's what the drug Xiletin does.

It inhibits the enzyme 5 -lipoxygenase, stopping the production line dead in its tracks.

Okay, let's compare them.

Why is Montelukas so popular, so widely used?

Well, it's an oral pill.

You take it once a day in the evening.

It's particularly effective for what's called aspirin -sensitive asthma, and it's generally very safe.

Xaprolukas is similar, but it has to be taken twice a day.

And crucially, you have to take it one to two hours before meals because food messes with its absorption.

What about drug interactions?

That's always a big concern.

Montelukas is pretty clean in that regard.

Xaprolukas, on the other hand, inhibits two important liver enzymes,

CYP2C9 and CYP3A4.

That means it can interfere with the metabolism of other drugs like the blood thinner warfarin or the seizure medication phenytoin leading to potential toxicity.

So Montelukas has a cleaner profile.

What about Xeluton, the synthesis inhibitor?

Xeluton has a theoretical advantage because it blocks the formation of all lupatrenes, and that includes one called LTB4, which the receptor blockers miss.

So in theory, it might be better for some severe cases, but it comes with some baggage.

What kind of baggage?

Liver toxicity.

You have to monitor the patient's liver enzymes regularly, which is a hassle.

And it also inhibits CYP1A2 and CYP3A4.

So it has interactions with drugs like theophylline and warfarin.

Plus, it has a short half life, so it needs to be dosed more often, although there are sustained release versions now.

The text also mentions a pretty scary sounding syndrome in the safety profile for these leukotriene modifiers, Churg -Strauss.

Yes, Churg -Strauss syndrome.

It's also known as allergic granulomatous vasculitis.

It is a rare but serious condition.

And the text notes that it has developed in some patients who are being withdrawn from steroid therapy while a leukotriene antagonist was being substituted in.

It's definitely something clinicians watch for very closely in that situation.

OK, let's hit section five quickly here.

The phosphodiesterase type 4 inhibitors, PDE4 inhibitors.

Right.

The drug here is rafflumelast.

This is a bit of a niche drug.

You don't see it as often.

It's a selective PDE4 inhibitor, and it's used specifically for severe COPD that's associated with chronic bronchitis.

So is it a bronchodilator?

Does it open the airways?

No, it is not.

It's an anti -inflammatory.

Its job is to reduce the number of exacerbations or flare ups.

It works by increasing the levels of SAM -MP inside immune cells, which calms them down.

The side effects listed in the text seemed a bit unusual for a lung medication.

Yes, they are.

Weight loss, diarrhea, and nausea are common gastrointestinal effects.

But the text also makes a point to highlight the psychiatric effects.

Anxiety, insomnia, and depression can occur in about 5 % of patients taking it.

So it's definitely not a first -line drug for everybody.

OK, so we're done with the anti -inflammatory squad.

We put out the fire, so to speak.

Now we move on to the bronchodilators.

These are the drugs that squeeze the muscle to make it relax.

First up,

the beta -2 agenoceptor agonists.

These are the ones everyone knows.

Albuterol, salmeterol.

They're the most common inhalers.

They work by activating the beta -2 receptors that are on the smooth muscle cells lining the airways.

And that does what?

Activating those receptors increases a chemical called cyclic AMP, or AMP.

And that leads to the relaxation of the muscle.

But I always hear people say their heart races when they take their inhaler.

Why does that happen if it's supposed to be targeting the lungs?

That's the selectivity issue.

We call them selective beta -2 agonists, but that selectivity isn't perfect.

At very high doses, they can start to hit the beta -1 receptors, which are primarily on the heart.

I see.

But also, and this is interesting, the human heart actually contains some beta -2 receptors as well.

Possibly 10 % to 50 % of the total beta receptors in the heart are beta -2.

So even if the drug is perfectly selective for beta -2, you're still going to stimulate the heart a little bit.

The chapter classifies these by their speed and duration.

Let's break down SEBA versus LABA.

Right.

SEBA stands for short -acting beta agonist.

Think albuterol and levelbuterol.

The onset of action is fast, like within five minutes.

And the duration is about three to eight hours.

These are your rescue inhalers.

You use them to stop an attack that's happening right now.

Exactly.

To terminate an acute attack.

The text mentions levelbuterol, which claims to have fewer side effects.

Does the evidence in the book hold that up?

The text is a little bit skeptical.

So levelbuterol is just the R enantiomer of racemic albuterol.

And while the claim is that it causes less tachycardia or rapid heart rate, the text cites a study showing no significant difference in heart rate effects when compared to regular albuterol.

Interesting.

Okay, so after the SEBAs, we have the LABAs.

Long -acting beta agonists.

Right.

Salmitorol and formoterol.

These last for about 12 hours.

They are for maintenance therapy, not rescue.

They are particularly good for preventing that dangerous nocturnal asthma we talked about earlier.

But there is a huge warning here.

The text mentions a black box warning.

That's serious.

It is.

The warning states that LABAs may increase the risk of asthma -related death if they are used alone as monotherapy.

Why?

The theory is that they treat the symptom the bronchoconstriction, the squeeze, but they can mask the underlying inflammation, the swell, which just continues to get worse in the background.

So for asthma, you must use a LABA in combination with an inhaled corticosteroid.

Never alone.

Got it.

And then there's one more category, the ultra -long -acting one.

That's Indicatorol.

It's a once -daily inhaler and it's approved specifically for the treatment of COQD, not for asthma.

Okay, let's move to section seven.

The muscarinic antagonists.

Eprotropium and Teotropium.

So these work on the other side of the autonomic nervous system.

While the beta agonists stimulate the sympathetic or fight -or -flight receptors to open the lungs, these drugs block the parasympathetic, rest and digest, signals that try to close them.

And they do that by blocking a specific neurotransmitter, right?

Acetylcholine.

Exactly.

They block the vagus nerve's constriction signal right at the muscarinic receptor.

The text seems to suggest that these are the real MVPs for COPD, maybe even more so than for asthma.

Why is that the case?

It seems that in COPD, something called vagal tone, that baseline nerve signal telling the airways to constrict, plays a much bigger role in the obstruction.

I see.

The text notes that Eprotropium is a bit slower to act than Albuterol, but its effects last longer.

And crucially, in COPD patients, the response to Albuterol can diminish over time.

It's a phenomenon called tachyphylaxis, but the response to Eprotropium is sustained even over weeks of treatment.

And Teotropium just takes that concept a step further.

It does.

Teotropium is the long -acting version, a llama.

It was actually the first once -daily inhaled treatment for COPD.

It improves lung function for a full 24 hours.

What are the main side effects we need to know?

Just think anticholinergic.

Dry mouth is the most common one by far.

Okay.

Section 8.

Thea Flank.

You called this one the coffee cousin earlier.

And it literally is.

It's a methiaxanthine, which is the same chemical class as caffeine, and it does similar things.

CNS stimulation, bronchodilation, and it's a diuretic.

So how does it work to open the airways?

Well, it's messy.

The mechanism isn't perfectly understood.

It seems to inhibit PDE enzymes.

It blocks adenosine receptors.

It inhibits calcium influx.

It does a little bit of everything to get the airways open.

It's not a very clean drug.

But the pharmacology, the pharmacogenetics specifically, that's where this drug gets really tricky, especially with smoking.

This is a classic board exam question.

So theophylline is metabolized by a liver enzyme called CYP1A2.

The chemicals in cigarette smoke are known to induce the synthesis of CYP1A2.

That means smoking makes your liver produce more of the enzyme that breaks down theophylline.

Wait, so a smoker needs a higher dose of the drug.

That seems so counterintuitive.

It is, but it's true.

They need a significantly higher dose.

A non -smoking adult has a half -life for the drug of about eight hours.

A smoker, only 4 .5 hours.

They clear it from their system almost twice as fast.

So what happens if a patient on a stable dose of theophylline suddenly quit smoking?

That's the danger.

If they stop smoking but stay on the same high dose, their metabolism slows down and their blood levels could spike into the toxic range very quickly.

And the toxic range for theophylline is very scary.

It has a what we call a narrow therapeutic index.

You want the blood levels to be between 5 and 15mgL.

If you get over 25mgL, you're at high risk for seizures and life -threatening cardiac dysrhythmias.

Is this drug still used very much today?

Its use is definitely declining.

It's mostly a third -line drug for COPD or severe asthma when nothing else is working.

It is also, interestingly, used for apnea in premature infants because it stimulates their central respiratory drive.

Okay, Section 9.

Now we're entering the really modern era monoclonal antibodies, the MABs.

Yep.

These are the injectable biologics.

Very high precision, very high -tech, and very expensive.

Let's start with the first one mentioned.

Omalizumab, brand name Exelair.

So Omalizumab targets IgE.

If you remember from the beginning, IgE is the antibody that really kicks off the allergic response.

Right, it sits on the mast cell.

Omalizumab is an antibody that binds to the IgE that's floating around in the blood.

It grabs it so that the IgE can't attach to the mast cell in the first place.

No attachment, no explosion.

So this is for patients with moderate to severe allergic asthma who have a positive skin test to an allergen.

Then we have a whole group that targets something called IL -5.

Right.

Interleukin -5, or IL -5, is a cytokine.

Its main job is to recruit and activate eosinophils, one of those key inflammatory cells.

So we have drugs like mepolizumab and reslizumab, which bind directly to the IL -5 itself, neutralizing it.

And there's another one that's slightly different.

Yes, benrolizumab.

It's a bit clever.

It binds to the IL -5 receptor on the eosinophil.

So it blocks the signal from ever getting in.

These drugs are all for patients with a specific type of severe asthma called eosinophilic phenotype asthma, where their disease is really driven by high eosinophil counts.

And what's the big safety warning with all of these maps?

Anaphylaxis.

You are injecting a foreign protein into the body, and there's always a risk of a severe allergic reaction.

The text says patients must be observed in the clinic for at least 30 minutes after each injection to make sure they don't have a hypersensitivity reaction.

Okay, that makes sense.

Section 10 is called putting it together.

It's about the actual management strategies.

The text describes a stepwise approach for asthma.

It's like a ladder, yeah.

You climb up the ladder as the patient's severity increases.

So step one is mild intermittent asthma.

For these patients, no daily drugs are needed.

They just have asaba, like albuterol, to use for rescue when symptoms pop up.

Okay, next step.

Step two, mild persistent.

Here you add a daily controller medication.

The first choice is a low -dose inhaled corticosteroid.

Or like with our 12 -year -old, you might consider montelucast.

And if that's not enough?

Step three, moderate persistent.

Now you either increase to a low or medium -dose inhaled steroid, plus you add a LOBA, the combination inhaler.

And the top of the ladder.

Step four, severe persistent.

That's a medium -dose inhaled steroid plus a labella.

And if even that fails, you start considering things like the monoclonal antibodies.

And what if someone comes into the ER and they can't breathe at all?

Stata sesameticus.

That's the full -blown emergency.

The protocol is oxygen, systemic steroids, usually given IV and continuous nebulized beta agonists.

You hit them with everything you've got.

What about managing rhinitis?

The runny nose.

For allergic rhinitis and histamines are key.

The text prefers the non -sedating ones like cetirizine or loratadine.

But it also notes that inhaled corticosteroids are actually the most efficacious anti -inflammatory option, even for the nose.

And for the common cold.

For viral rhinitis, treatment is conservative.

Symptom management, analgesics for the aches and pains, decongestants for the stuffiness.

The text mentions the herbal supplement echinacea.

What's the verdict on that?

It's cautious.

It notes that some studies suggest short -term use -like for 10 days may help shorten the severity of a cold.

But it specifically warns that long -term use might actually suppress the immune system, which is the opposite of what you want.

Good to know.

Okay, section 11, symptom management.

Let's talk about cough and mucus.

We have antitussives, which are cough suppressants and expectorants.

For the suppressants, you have opioids like codeine and hydrocodone.

They work centrally on the cough center in the medulla of the brain.

But the more common one is dextromethorphin, the DM you see in all the drugstore cough syrups.

And what's special about that one?

It's interesting.

It's the de -isomer of an opioid agonist.

So chemically, it's related.

It suppresses the cough reflex.

But at normal doses, it doesn't cause the drowsiness or analgesia or euphoria that you'd get with opioids.

Then we have expectorants.

Y -finicin.

Yosemite.

Yosemite.

The text is a little funny here, actually.

It says it is purported to reduce the surface tension and adhesiveness of mucus.

Purported.

Yeah.

It essentially admits that the exact mechanism is not really known.

But the goal, the idea, is to thin out the mucus and make it easier for you to cough that thick stuff up and out.

Finally, we've reached section 12.

Cystic fibrosis.

This is a very heavy disease.

But the pharmacology here is just incredible.

It really is.

So CF is a genetic disorder.

It's caused by a mutation in the CFTR gene.

This gene is supposed to make a chloride ion channel.

When that channel is broken, chloride can't get out of the epithelial cells, water doesn't follow the salt, and you end up with this incredibly thick, sticky mucus that plugs up the lungs, the pancreas, and other organs.

And for a long time, the treatments were just supportive.

But now we have eucalyptics, like Dornaise Alpha.

Right.

Brand name Pulmozyme.

It's recombinant human DNA.

So it's a lab -made version of an enzyme our body naturally produces.

And what does it do?

In CF patients, the mucus is full of DNA that's been left behind by dead white blood cells that were fighting infection.

That DNA is like a net, making the mucus really thick and sticky.

Dornaise Alpha acts like molecular scissors.

It goes in and chops up all that extracellular DNA, which thins the mucus out so the patient can clear it.

But the real game changers are the CFTR modulators.

These are just astounding.

They target the broken protein itself.

You have a drug called ivacaftor, which is a potentiator.

For certain mutations where the channel gets to the cell surface but is stuck closed, ivacaftor basically props the gate open to let the chloride through.

It works for specific mutations, like G551D.

And then there's another class.

Yes.

A drug like lumacaftor is a chaperone.

For the most common CF mutation, F508, said all, the protein is misfolded and never even gets to the cell surface.

Lumacaftor helps it fold correctly so the cell can transport it to the membrane where it belongs.

And if you put them together?

You get combination drugs like orcombi, which is lumacaftor plus ivacaftor.

It's designed specifically to address that common F508 -ADL mutation.

One drug acts as the chaperone to get the protein to the door, and the other one acts as the potentiator to open the door.

It's precision medicine at its absolute finest.

It's incredible.

So we've gone from old school treatments like inhaling smoke or taking coffee derivatives to these genetically targeted protein chaperones.

It's a massive evolution.

We started with these very blunt tools like theophylline that hit everything.

And now we have these guided missiles like the monoclonal antibodies and the CFTR modulators that target one specific molecule.

So as we wrap this up, what's the final thought for the listener, the big takeaway from this whole chapter?

I think it's that pharmacology is about balance, especially in respiratory disease.

In asthma, we're constantly trying to balance suppressing the inflammation, the swell with the steroids, and opening the pipes, the squeeze with the bronchodilators.

We're constantly intervening in these incredibly complex biological cascades, the arachidonic acid pathway, calcium influx, vagal tonal, to try and restore that simple, automatic, invisible act of breathing.

And with that, we wrap up our deep dive into respiratory pharmacology.

It was a pleasure.

A warm thank you from the last -minute lecture team.

Keep breathing easy, everyone.